Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei 106, Taiwan.
GENTIS JSC, 249A, Thuy Khue, Tay Ho, Hanoi 100000, Vietnam.
Biosensors (Basel). 2021 Aug 25;11(9):295. doi: 10.3390/bios11090295.
The development of reliable and robust diagnostic tests is one of the most efficient methods to limit the spread of coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, most laboratory diagnostics for COVID-19, such as enzyme-linked immunosorbent assay (ELISA) and reverse transcriptase-polymerase chain reaction (RT-PCR), are expensive, time-consuming, and require highly trained professional operators. On the other hand, the lateral flow immunoassay (LFIA) is a simpler, cheaper device that can be operated by unskilled personnel easily. Unfortunately, the current technique has some limitations, mainly inaccuracy in detection. This review article aims to highlight recent advances in novel lateral flow technologies for detecting SARS-CoV-2 as well as innovative approaches to achieve highly sensitive and specific point-of-care testing. Lastly, we discuss future perspectives on how smartphones and Artificial Intelligence (AI) can be integrated to revolutionize disease detection as well as disease control and surveillance.
开发可靠和稳健的诊断测试是限制 2019 年冠状病毒病（COVID-19）传播的最有效方法之一，COVID-19 是由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的。然而，大多数 COVID-19 的实验室诊断方法，如酶联免疫吸附测定（ELISA）和逆转录-聚合酶链反应（RT-PCR），既昂贵又费时，且需要经过高度训练的专业操作人员。另一方面，侧向流动免疫分析（LFIA）是一种更简单、更便宜的设备，未经训练的人员也可以轻松操作。不幸的是，目前的技术存在一些局限性，主要是检测的准确性不高。本文综述旨在强调新型侧向流动技术在检测 SARS-CoV-2 方面的最新进展，以及实现高灵敏度和特异性即时检测的创新方法。最后，我们讨论了智能手机和人工智能（AI）如何整合来彻底改变疾病检测以及疾病控制和监测的未来展望。
